Literature DB >> 31732287

EWGSOP2 versus EWGSOP1 for sarcopenia to predict prognosis in patients with gastric cancer after radical gastrectomy: Analysis from a large-scale prospective study.

Cheng-Le Zhuang1, Xian Shen2, Hong-Bo Zou3, Qian-Tong Dong3, Hui-Yang Cai3, Xiao-Lei Chen3, Zhen Yu4, Su-Lin Wang5.   

Abstract

BACKGROUND: In 2010, the European Working Group on Sarcopenia in Older People (EWGSOP) reached a consensus on sarcopenia (EWGSOP1). In 2018, the EWGSOP met again (EWGSOP2) to update original definition of sarcopenia. This study aimed to investigate the association of sarcopenia and survival and compare the prognostic effects of sarcopenia as defined by EWGSOP1 and EWGSOP2 after gastrectomy.
METHODS: We conducted a prospective study including patients who underwent curative gastrectomy for gastric cancer from August 2014 to February 2018. The sarcopenia elements, including skeletal muscle index, muscle attenuation, handgrip strength, and gait speed were measured before surgery. Patients were followed up after gastrectomy to gain the actual clinical outcomes.
RESULTS: The prevalence of sarcopenia was 17.0% and 18.9% according to the EWGSOP1 and EWGSOP2 respectively. Sarcopenia was independent risk factor for postoperative complications. Compared with EWGSOP1-sarcopenia, EWGSOP2-sarcopenia and had a higher odds ratio (OR) (2.453 vs. 1.550) in multivariate model. Area under the ROC curve of model including EWGSOP2-sarcopenia was larger than that of the model including EWGSOP1-sarcopenia (AUC 0.653 vs. 0.634, P = 0.021). For both of EWGSOP1 and EWGSOP2, sarcopenia was an independent risk factor for overall survival (OS) and disease-free survival (DFS), but EWGSOP2-sarcopenia seemed to have a higher hazard ratio (OS, 1.667 vs. 1.449; DFS, 1.603 vs. 1.563). In addition, severe sarcopenia, as defined by either EWGSOP2 or EWGSOP1, had a strong predictive power (OR 4.909 vs. 3.827) for postoperative complications. Both versions of severe sarcopenia were significantly predictive of OS and DFS in Cox analysis.
CONCLUSION: Sarcopenia at uniform diagnosis standard was an independent risk factor for survival in patients undergoing radical gastrectomy for gastric cancer. Sarcopenia defined by EWGSOP2 criteria better predicts clinical outcomes than that defined by EWGSOP1 criteria in patients with gastric cancer after gastrectomy.
Copyright © 2019 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Keywords:  EWGSOP2; Gastric cancer; Sarcopenia

Year:  2019        PMID: 31732287     DOI: 10.1016/j.clnu.2019.10.024

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  13 in total

1.  Establish a New Diagnosis of Sarcopenia Based on Extracted Radiomic Features to Predict Prognosis of Patients With Gastric Cancer.

Authors:  Xiao-Dong Chen; Wen-Jing Chen; Ze-Xin Huang; Li-Bin Xu; Hui-Hui Zhang; Ming-Ming Shi; Yi-Qi Cai; Wei-Teng Zhang; Zhao-Shen Li; Xian Shen
Journal:  Front Nutr       Date:  2022-06-28

2.  Sarcopenia and mortality risk in community-dwelling Brazilian older adults.

Authors:  Cristina Camargo Pereira; Valéria Pagotto; Cesar de Oliveira; Erika Aparecida Silveira
Journal:  Sci Rep       Date:  2022-10-20       Impact factor: 4.996

Review 3.  Nutrition update in gastric cancer surgery.

Authors:  Takeshi Kubota; Katsutoshi Shoda; Hirotaka Konishi; Kazuma Okamoto; Eigo Otsuji
Journal:  Ann Gastroenterol Surg       Date:  2020-06-08

4.  Profiles Combining Muscle Atrophy and Neutrophil-to-Lymphocyte Ratio Are Associated with Prognosis of Patients with Stage IV Gastric Cancer.

Authors:  Kota Shigeto; Takumi Kawaguchi; Shunji Koya; Keisuke Hirota; Toshimitsu Tanaka; Sachiko Nagasu; Masaru Fukahori; Tomoyuki Ushijima; Hiroo Matsuse; Keisuke Miwa; Koji Nagafuji; Takuji Torimura
Journal:  Nutrients       Date:  2020-06-24       Impact factor: 5.717

5.  Sarcopenia is poor risk for unfavorable short- and long-term outcomes in stage I non-small cell lung cancer.

Authors:  Yusuke Takahashi; Shigeki Suzuki; Kenichi Hamada; Takeo Nakada; Yuko Oya; Noriaki Sakakura; Hirokazu Matsushita; Hiroaki Kuroda
Journal:  Ann Transl Med       Date:  2021-02

6.  Sarcopenia in hospitalized geriatric patients: insights into prevalence and associated parameters using new EWGSOP2 guidelines.

Authors:  Dominic Bertschi; Caroline M Kiss; Nadine Beerli; Reto W Kressig
Journal:  Eur J Clin Nutr       Date:  2020-10-15       Impact factor: 4.016

7.  Systematic review and meta-analysis of lean mass and mortality: Rationale and study description.

Authors:  Ching-Lung Cheung; Grace Koon-Yee Lee; Philip Chun-Ming Au; Gloria Hoi-Yee Li; Marcus Chan; Hang-Long Li; Bernard Man-Yung Cheung; Ian Chi-Kei Wong; Victor Ho-Fun Lee; James Mok; Benjamin Hon-Kei Yip; Kenneth King-Yip Cheng; Chih-Hsing Wu
Journal:  Osteoporos Sarcopenia       Date:  2021-02-11

8.  Sarcopenia and Liver Cirrhosis-Comparison of the European Working Group on Sarcopenia Criteria 2010 and 2019.

Authors:  Julia Traub; Ina Bergheim; Martin Eibisberger; Vanessa Stadlbauer
Journal:  Nutrients       Date:  2020-02-20       Impact factor: 5.717

Review 9.  Molecular Mechanism Contributing to Malnutrition and Sarcopenia in Patients with Liver Cirrhosis.

Authors:  Fatuma Meyer; Karen Bannert; Mats Wiese; Susanne Esau; Lea F Sautter; Luise Ehlers; Ali A Aghdassi; Cornelia C Metges; Leif-A Garbe; Robert Jaster; Markus M Lerch; Georg Lamprecht; Luzia Valentini
Journal:  Int J Mol Sci       Date:  2020-07-28       Impact factor: 5.923

10.  Does prehabilitation modify muscle mass in patients with rectal cancer undergoing neoadjuvant therapy? A subanalysis from the REx randomised controlled trial.

Authors:  S J Moug; S J E Barry; S Maguire; N Johns; D Dolan; R J C Steele; C Buchan; G Mackay; A S Anderson; N Mutrie
Journal:  Tech Coloproctol       Date:  2020-06-20       Impact factor: 3.781

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.